权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of A Novel Anti-Hyperglycemic Agent

新型抗高血糖药的研制

基本信息

批准号：
8196299
负责人：
Zhaoping Li
金额：
--
依托单位：
VA GREATER LOS ANGELES HEALTHCARE SYSTEM
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-01 至 2012-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8196299
关键词：
Adverse effects Adverse event Agreement Alzheimer&apos s Disease Amino Acids Animal Model Animals Asians Blood Blood Glucose Bone Density Brain Cardiovascular system Cause of Death Cell membrane Cells Centers for Disease Control and Prevention (U.S.)Chemistry Chronic Disease Clinical Clinical Trials Complex Copper Country Cytosol Defect Development Diabetes Mellitus Diabetes prevention Dipeptides Disease Dose Double-Blind Method Drops Environmental Risk Factor Enzyme Gene Enzymes European Event Expenditure FDA approved Fasting Future Gel Genes Genetic Genetic Polymorphism Glucagon Glucose Glucose Intolerance Glucose Transporter Glucose tolerance test Glycosylated hemoglobin A Health Healthcare Hematology Hepatic High Prevalence Hour Human Hyperglycemia Hypoglycemia Hypoglycemic Agents Impairment Injection of therapeutic agent Inpatients Insulin Insulin Receptor Insulin Resistance Insulinase Intake Intestines Kidney Lead Legal patent Leptin Literature Liver Liver Failure Marketing Mediating Medical Medical center Metformin Molecular Muscle Mutation National Health and Nutrition Examination Survey Nausea Non-Insulin-Dependent Diabetes Mellitus Obesity Oral Oral Administration Outcome Outcome Study Outpatients Patients Peptide Hydrolases Peptides Peripheral Pharmaceutical Preparations Pharmacy facility Phase Phase I Clinical Trials Pioglitazone Placebo Control Placebos Plasma Play Population Prevention Process Proteins Randomized Rattus Receptor Signaling Recruitment Activity Regimen Reporting Research Research Design Risk Role SLC2A1 gene Safety Services Severe Adverse Event Signal Transduction Stomach Sulfonylurea Compounds Symptoms Therapeutic Agents Thyroid Function Tests Tissues United States Urine Veterans Visit Vomiting Zinc Zinc deficiency absorption adiponectin analog base brain tissue capsule commercialization cost diabetic diabetic patient diet and exercise effective therapy experience fasting plasma glucose four-arm study functional disability glucogenesis glucose metabolism glucose output glucose uptake glycemic control histidylproline improved inhibitor/antagonist insulin sensitivity insulin signaling novel oral glucose tolerance primary outcome public health relevance receptor recycling rosiglitazone secondary outcome volunteer week trial

项目摘要

DESCRIPTION (provided by applicant): We have demonstrated that a cyclic dipeptide Cyclo (his-pro) plus zinc (Cyclo-Z) treatment improved clinical conditions of diabetes in various animal models and a phase 1 clinical trial. The main objective of this study is to demonstrate that this product is safe and effective for the treatment of human diabetes. Research Plan This is a randomized, double blinded, placebo-controlled, and parallel study. In this study, we will recruit 120 hypoglycemic drug naove type 2 diabetic patients and randomize them into 4 groups of 30 subjects each to compare the effects of a Cyclo-Z capsule containing CHP 0 (placebo), 3 mg (minimally effective), 9 mg (optimally effective), or 15 mg (no-additional effect) plus 20 mg zinc on diabetic symptoms in a 12-week trial period. The primary outcome of this study is improvement of hemoglubin A1c; secondary outcomes are fasting blood glucose, 2 hours postprandial glucose and glucose tolerance test. Safety will be assessed by the presence of severe adverse events (SAEs), adverse events (AEs), any changes of vital signs, physical exams, blood hematology, chemistry, liver, renal, thyroid function tests, urine analysis and zinc, copper levels. PUBLIC HEALTH RELEVANCE: Relevance to the Veterans Health Diabetes is a difficult and challenging chronic disease, and the seventh leading cause of death in the US (61). The DVA provides healthcare service to about 5.0 million patients throughout the country in 163 medical centers, and diabetes has high prevalence in VA patients. In the year 2000, 19.6% of VA patients had diabetes and this percentage increases annually by 2 % (61). Hence, the diabetic population among VA patients may approach 30% in the year 2008. About 30 % of pharmacy prescriptions of the VA Medical Centers are received by diabetic patients (62) and overall 23 % of pharmacy expenditures were related to patients' glycemic control in the year 2000. The expenditure for the outpatient visits was $214.8 million and inpatient expenditure was $1.45 billion in 1998 (63). Cyclo-Z may pose a benefit to more than 30% of veteran population. This new drug may ameliorate diabetes and reduce insulin-resistance which would greatly reduce the cost of inpatient and outpatient medical service as well as pharmacy expenditure. Three different patents with Cyclo-Z for the treatment of diabetes, obesity and Alzheimer's disease are now owned by the DVA and the phase 1 clinical trial has been completeds with favorable result. The outcome of the proposed phase 2a clinical trial will lead to an agreement with a major drug company by the DVA for Cyclo-Z marketing. We believe that Cyclo-Z will be effective and safe in the prevention and treatment of diabetes and that this novel drug will be beneficial to the health of many diabetic veteran patients.

描述（由申请人提供）：我们已经证明，环二肽Cyclo（his-pro）加锌（Cyclo-Z）治疗在各种动物模型和1期临床试验中改善了糖尿病的临床状况。本研究的主要目的是证明本品治疗人类糖尿病安全有效。研究计划这是一项随机、双盲、安慰剂对照和平行研究。在这项研究中，我们将招募120名未经降糖药物治疗的2型糖尿病患者，并将他们随机分为4组，每组30名受试者，以比较在12周的试验期内，含有CHP 0（安慰剂），3 mg（最低有效），9 mg（最佳有效）或15 mg（无额外作用）加20 mg锌的Cyclo-Z胶囊对糖尿病症状的影响。本研究的主要结局是血红蛋白A1 c的改善;次要结局是空腹血糖、餐后2小时血糖和糖耐量试验。将通过是否存在重度不良事件（SAE）、不良事件（AE）、生命体征、体格检查、血液学、生化、肝脏、肾脏、甲状腺功能检查、尿液分析和锌、铜水平的任何变化来评估安全性。公共卫生相关性：与退伍军人健康的相关性糖尿病是一种困难和具有挑战性的慢性疾病，是美国第七大死亡原因（61）。DVA在全国163个医疗中心为约500万患者提供医疗服务，糖尿病在VA患者中的患病率很高。2000年，19.6%的VA患者患有糖尿病，并且这一比例每年增加2%（61）。因此，VA患者中的糖尿病人群可能在2008年接近30%。2000年，VA医疗中心约30%的药房处方由糖尿病患者（62）接受，总体上23%的药房支出与患者的血糖控制有关。1998年，门诊费用为2.148亿美元，住院费用为14.5亿美元（63）。Cyclo-Z可能对30%以上的退伍军人有益。这种新药可以改善糖尿病和降低胰岛素抵抗，从而大大降低住院和门诊医疗费用以及药房费用。目前，DVA拥有三项不同的Cyclo-Z治疗糖尿病、肥胖症和阿尔茨海默病的专利，并已完成1期临床试验，取得了良好的结果。拟议的2a期临床试验的结果将导致DVA与一家主要制药公司就Cyclo-Z的营销达成协议。我们相信Cyclo-Z在预防和治疗糖尿病方面将是有效和安全的，并且这种新药将有益于许多糖尿病退伍军人患者的健康。